TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

Benzinga Logo Benzinga By Vandana Singh
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

Amgen acquired Dark Blue Therapeutics for up to $840 million to strengthen its oncology pipeline. Dark Blue's lead candidate DBT 3757 targets acute myeloid leukemia and acute lymphoblastic leukemia. The acquisition complements Amgen's targeted protein degradation research and advances its early-stage cancer medicine strategy.

Insights
AMGN   positive

Strategic acquisition strengthens oncology pipeline and early-stage cancer research capabilities. Stock up 2.89% at publication, approaching 52-week high. Recent FDA approval of Uplinza demonstrates pipeline strength.